quantisnow
FeedTopReportsPricing
⌘K
Live feed
12:43:07·518d
FDARegulatory
Amgen Inc. logo

FDA Approval for REPATHA issued to AMGEN INC

AMGN· Amgen Inc.
Health Care
Original source

Companies

  • AMGN
    Amgen Inc.
    Health Care

Recent analyst ratings

  • Apr 21UpdateCanaccord Genuity$366.00
  • Mar 10UpdateJefferies$350.00
  • Feb 20UpdateBarclays$185.00
  • Jan 20UpdateBernstein$335.00
  • Jan 7UpdateUBS$380.00
  • Dec 5UpdateErste Group-

Related

  • SEC1d
    Amgen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
  • PR1d
    AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
  • SEC2d
    SEC Form DEFA14A filed by Amgen Inc.
  • ANALYST2d
    Canaccord Genuity initiated coverage on Amgen with a new price target
  • SEC8d
    SEC Form DEFA14A filed by Amgen Inc.
  • SEC16d
    SEC Form DEFA14A filed by Amgen Inc.
  • SEC16d
    SEC Form DEF 14A filed by Amgen Inc.
  • PR17d
    AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022